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Abstract 
Background: Platelets are known contributors to the vascularization, metastasis and growth of tumors. Upon their 
interaction with cancer cells they are activated resulting in degranulation and release of constituents. Since the apop-
totic- and autophagic effects of 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16) has been shown to occur 
in vitro and this compound was designed to bind to carbonic anhydrase II (CAII), the possible occurrence of these cell 
death mechanisms in platelets as circulatory components, is of importance.
Methods: Scanning electron microscopy was used to assess morphological changes in platelets after exposure to 
ESE-16. The possible apoptotic- and autophagic effect of ESE-16 in platelets was also determined by means of flow 
cytometry through measurement of Annexin V-FITC, caspase 3 activity, autophagy related protein 5 levels and light 
chain 3-I to light chain 3-II conversion.
Results: Scanning electron microscopy revealed no changes in ESE-16-treated platelets when compared to vehicle-
treated samples. Apoptosis detection by Annexin V-FITC and measurement of caspase 3 activity indicated that there 
was no increase in apoptosis when platelets were exposed to ESE-16. The incidence of autophagy by measurement 
of autophagy related protein 5 levels and light chain 3-I to light chain 3-II conversion showed that exposure to ESE-16 
did not cause the incidence of autophagy in platelets.
Conclusion: This is the first ex vivo study reporting on involvement of apoptosis- and autophagy-related targets in 
platelets after exposure to ESE-16, warranting further investigation in platelets of cancer patients.
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Background
Apoptosis is a form of cell death, which is closely asso-
ciated with occurrences within the nucleus, and is con-
sequently questioned in platelets since they lack the 
nuclear machinery typically considered to result in apop-
tosis. Interestingly, platelets display characteristic signs 
of nucleated apoptosis including membrane blebbing, 
loss of the integrity of the platelet membrane and micro-
particles release [1, 2]. The ability of platelets to undergo 
apoptosis is a result of the presence of mitochondria 
which contribute mitochondrial deoxyribonucleic acid 
(DNA) and messenger ribonucleic acid (mRNA) which 
aid in the platelets’ ability to synthesise proteins con-
tained within platelet granules [3, 4].
Thus, even though platelets do not possess a nucleus, 
they exhibit biological apoptotic signals during stress 
conditions including activation of caspase 3 and expo-
sure/externalisation of phosphatidylserine [5]. Kile [6] 
showed that platelets do undergo apoptosis via the intrin-
sic apoptotic pathway, which also regulates the platelets’ 
lifespan. Platelets abundant mitochondria are known to 
be associated with the intrinsic apoptotic pathway or 
mitochondrial pathway [7].
The intrinsic apoptotic pathway is characterised by 
activation of Bak and Bax, triggering damage of the mito-
chondria and releasing cytochrome c and other apop-
totic proteins from the mitochondrial intermembrane 
space. The release of cytochrome c allows for the forma-
tion of the apoptotic protease activating factor 1 (Apaf-1) 
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apoptosome and subsequent recruitment of initiator pro-
caspase 9. Binding to the apoptosome activates caspase 
9 and resulting activation of effector caspase 3, result-
ing in the execution phase of apoptosis [6]. Upstream of 
caspase 3 activation and phosphatidylserine (PS) expo-
sure, the mitochondrial inner transmembrane potential 
is depolarized in platelets, similar to the mechanism of 
nucleate cellular apoptosis [3].
The resulting externalisation of PS allows for removal 
of apoptotic platelets. In platelets, PS is also expressed 
on the cell surface, however, can only be recognized by 
macrophages for phagocytosis by recognition via human 
cluster of differentiation 36 (CD36) present on the mem-
brane of human platelets [3, 5–7]. The externalisation 
of PS in platelets, however, seems to also occur inde-
pendently of the intrinsic apoptotic pathway, playing an 
important role in formation of thrombin by assembling 
the pro-thrombinase complex [6, 7].
In addition to apoptosis in platelets, the role of 
autophagy and the biological markers thereof have not 
been researched extensively in platelets. Since platelets 
do contain small amounts of functional mitochondria, it 
has been proposed to share characteristics of nucleated 
autophagy mechanisms and markers [8]. Autophagy’s 
ability to maintain cellular homeostasis and adjustment 
to starvation is of importance in platelets since their 
lifespan is only about 10  days in humans [9]. However, 
autophagy can also be triggered continuously under cer-
tain stress conditions such as starvation, cellular injury 
and contact with certain chemicals, which lead the cell 
to progressively degrade vital cytoplasmic components, 
essentially digesting itself [9].
The occurrence of autophagy is not well documented 
in platelets; literature reveals a research gap in determin-
ing whether autophagy occurs in platelets and by which 
mechanisms it is regulated. One such a study was con-
ducted by Feng et  al., where researchers showed that 
platelets do express autophagy-related gene (Atg) pro-
teins and the process is also activated by the inhibition of 
mammalian target of rapamycin (mTOR) [10]. The occur-
rence of autophagy in platelets is essential in maintaining 
homeostasis within platelets and in the number of plate-
let populations [10]. A defect in platelet autophagy may 
result in compromised platelet adhesion and aggregation 
[10].
Platelets also serve as way for tumors to increase 
growth and provide physical and mechanical support to 
elude the immune system and metastasize [11, 12]. Due 
to the fact that platelets play an important role in cancer 
and tumor development, the effect of potential antican-
cer drugs on platelets will provide research data regard-
ing its role in cancer progression.
Cancer metastasis is directly linked to platelet activity 
and in particular the ability of cancer cells to elude the 
immune system by formation of platelet-tumor aggre-
gates [13]. This takes place through the binding of can-
cer cells (from various cancer cell lines) to P-selectin and 
integrins expressed on the membrane of platelets thus 
activating them.
Testing of newly synthesized compounds on cancer cell 
lines allows for the opportunity to determine the mech-
anisms of action and the possible effects and success of 
these compounds as potential anticancer compounds. 
Our laboratory has determined the aforementioned 
effects of ESE-16 on cancer cell lines including tumo-
rigenic human epithelial cervical HeLa cell line, MCF-7 
breast cancer cell line, esophageal carcinoma SNO cell 
line and the metastatic MDA-MB-231 breast cancer cell 
line, whilst also being tested on the non-tumorigenic 
MCF-12A breast cells to assure cancer cell selectivity 
[14–16]. However, since ESE-16 was designed to revers-
ibly bind to CAII in the blood stream to bypass the first 
pass of metabolism in the liver, thereby increasing its bio-
availability, its resulting effects on blood components is 
of extreme importance [17]. Platelets, in particular, pre-
sent with specific characteristics making them a target 
for cancer studies [18].
The ex  vivo effect of ESE-16 on platelets and possible 
instigation of apoptosis and autophagy have not been 
reported in literature. We investigated the role platelets 
may play after exposure to ESE-16 and how exposure to 
ESE-16 will influence apoptosis and thus the incidence 
of externalisation of PS and caspase 3 in healthy human 
platelets. Results provide with substantial evidence that 
future in vivo studies with ESE-16 are plausible and that 




Citrate tubes (with citrate as anticoagulant causing 
chelation of extracellular calcium [19]) and needles 
were acquired from transpharm (Gauteng, SA). Micro-
plates (96 well) were obtained from Separation Scien-
tific (Randburg, Johannesburg, SA). Phosphate-buffered 
saline (PBS) was purchased from Gibco-BRL (Invitrogen, 
Carlsbad, CA, USA) and prepared as a tenfold concen-
trated stock solution consisting of 80 g/l NaCl, 2 g/l KCl, 
2  g/l KH2PO4 and 11.5  g/l Na2PO4. The latter was pre-
pared in double distilled water (ddH2O) and the pH was 
adjusted to 7.4. A one times solution of PBS was made 
with ddH2O as a 1:10 dilution of the tenfold stock and 
subsequently autoclaved (120  °C, 15 psi, 20 min) before 
use. Dimethyl sulphoxide (DMSO) and propidium iodide 
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were supplied by Sigma-Aldrich Co. (St. Louis, USA). All 
blood contaminated waste materials were collected and 
discarded into 5L Biological waste bins (Sharps bin). Bins 
were handed over to Oricol Environmental Services.
Preparation of compounds
ESE-16 is a novel analogue of 2-methoxyestradiol which 
has been in silico-designed at the Bioinformatics and 
Computational Biology Unit, Department of Biochem-
istry, University of Pretoria, South Africa. Synthesis of 
ESE-16 was conducted by Ithemba Pharmaceuticals 
(Pty) Ltd and ESE-16 was dissolved in dimethyl sul-
foxide of which the final concentration did not exceed 
0.01  % (v/v) in platelet samples [20]. Platelet sam-
ples were exposed to 0.20  μM of ESE-16 [17] for 24  h 
at 22  °C which was selected as it has been previously 
established that 0.18 μM ESE-16 inhibits cell growth by 
50 % (GI50) after 24 h at 37 °C [17, 21, 22]. Platelet sam-
ples were exposed for 24 h at 22 °C as this temperature 
has been determined to be comparable to that of fridge 
temperatures for platelet storage in order to maintain 
platelet viability [1]. Controls included DMSO at a con-
centration of 0.01  % as vehicle control (v/v), untreated 
platelets as negative control, 2-methoxyestradiol-bis-
sulphamate-treated (2MEBM) platelets at a concentra-
tion of 1  µM and platelets treated with 4  % DMSO as 
positive controls [23].
Methods
Study design and sampling method
Blood was collected from 3 healthy female individuals 
working at the Department of Physiology (University 
of Pretoria) and aged between 20 and 45 who did not 
smoke or use any medication. Participants who met the 
following exclusion criteria were involved in the study: 
chronic or acute illnesses, autoimmune diseases, heredi-
tary diseases, hypertension, contraceptives, or smoking. 
As breast cancer is the second leading cause of mortality 
of females globally and first leading cause in sub-Saharan 
Africa with poor survival rates, female participants were 
chosen for this study, to determine possible future clini-
cal applications [24, 25]. Even though the compounds 
tested in this study are derived from 17β-estradiol, the 
compounds do not bind selectively to estrogen receptors, 
yet rather to CAII [17, 21, 22].
Blood samples were taken after an 8  h period of fast-
ing between 08:00 and 09:00 am. Whole blood was col-
lected in citrate tubes and platelet rich plasma (PRP) was 
obtained by centrifuging the blood at 1000 rpm for 2 min 
and collecting plasma from the separated blood [26]. The 
PRP was centrifuged further, supernatant was discarded 
and platelets were resuspended in plasma.
Scanning electron microscopy
The scanning electron microscope (SEM) is used to view 
the surface and surface molecules of samples with the use 
of high-energy electrons which reflected off the surface of 
the solid coated specimen surface to present a high-qual-
ity image [27]. Morphology of platelet samples exposed 
to ESE-16 at 24 h to determine effects at this time inter-
val equivalent to exposure of cancer cell lines at 22 °C was 
viewed.
Ex vivo samples were prepared on the glass plates with 
10 µl platelets (107 platelets/ml) as a control, 10 µl plate-
lets exposed to ESE-16, 10 µl platelets exposed to DMSO 
and 10 µl platelets exposed to positive control 2-methox-
yestradiol-bis-sulphamate and 4  % DMSO. Glass plates 
with ex  vivo samples were placed in 6 well plates and 
left to dry slightly, after which the samples were washed 
for 20  min in a 50  % PBS: 50  % distilled H2O solution. 
Samples were fixed with 2.5  % gluteraldehyde and PBS 
for 30 min and washed 3 times in PBS for 3 min each for 
subsequent secondary fixation in osmium tetraoxide for 
15 min. Samples were washed 3 times each for 3 min and 
dehydrated for 3 min each in increasing concentration of 
ethanol, 30, 50, 70, 90 % and three times in 100 % ethanol 
[26]. Samples were critically dried, mounted and carbon 
coated and viewed with the Zeiss ULTRA plus FEG-SEM 
[Carl Zeiss (Pty) Ltd, Johannesburg, South Africa]. Quali-
tative SEM images were obtained from 3 independent 
experiments repeated for each participant. Representa-
tive images were included to represent all 3 repeats.
Measurement of phosphatidyl‑serine (PS) flip via annexin 
V‑fluorescein isothiocyanate
During apoptosis, activation of calcium-dependent phos-
pholipid scramblase causes the symmetry of the phos-
pholipid content of the cell membrane to be lost [28]. 
This occurs in platelets following activation and results 
in the externalization of the phospholipid layer which can 
be detected using the PS-binding protein, annexin V [29].
Platelets were obtained and exposed as previously 
described. Platelet samples were resuspended in 100  µl 
of the 1 × binding buffer. Subsequently, 10 µl of annexin 
V-fluorescein isothiocyanate (FITC) was added and incu-
bated for 15  min in the dark at room temperature as 
described in supplier manual from MACS (Miltenyi Bio-
tec GmbH) [29]. After incubation, samples were washed 
with 1  ml 1 ×  binding buffer and centrifuged at 300×g 
for 10  min. The supernatant was carefully pipetted off 
and samples were resuspended in 500  µl 1  ×  binding 
buffer solution. Annexin V fluorescence was measured 
with a FC500 System flow cytometer equipped with an 
air-cooled argon laser with an excitation wavelength of 
488  nm. 10,000–30,000 events were counted for each 
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repeat and analysis of the data was done with the use of 
Cyflogic version 1.2.1 software.
Measurement of caspase 3 activity
Caspase 3, an execution caspase in the apoptotic path-
ways and upon activation, cleaves various proteins which 
results in the characteristic qualities of apoptosis includ-
ing formation of apoptotic bodies [30]. Activation of cas-
pase 3 due to ESE-16-exposure was investigated with the 
use of flow cytometry [31].
Samples were washed in wash buffer and centrifuged 
at 250×g for 5 min and the pellet was fixed by the addi-
tion of fixation buffer (0.1  % formaldehyde) and incu-
bated at room temperature for 20  min. Samples were 
then centrifuged at 10,000×g for 1 min and supernatant 
was discarded. Cells were washed once in assay buffer 
[containing 1  % bovine serum albumin (BSA)] and cen-
trifuged. Samples were suspended in 500  µl cold Per-
meabilization buffer (100 % methanol) and incubated on 
ice for 10  min. Cells were centrifuged, supernatant dis-
carded and washed in assay buffer. Samples were spun 
down, suspended in 100 µl Assay buffer with a 1:100 dilu-
tion of the primary antibody, rabbit anti-active caspase 3 
[IMGENEX (San Diego, California, USA) purchased from 
BIOCOM Biotech (Pty) Ltd. (Pretoria, Gauteng, South 
Africa)] and incubated for 90  min on ice, after which 
900 µl Assay buffer was added to wash the samples. Sam-
ples were subsequently washed twice with 500  µl Assay 
buffer, spun down, resuspended in 100  µl Assay buffer 
and incubated for 1 h in the dark with 0.2 µg/ml of the 
secondary antibody, anti-rabbit antibody conjugated to 
Dylight™ 488 fluorochrome [Rockland Inc. (Gilbertsville, 
Pennsylvania, USA) purchased from BIOCOM Biotech 
(Pty) Ltd. (Pretoria, Gauteng, South Africa)]. Afterwards 
900 µl of the Assay buffer was added to wash the samples, 
centrifuged and washed twice more with 500  µl assay 
buffer. Cells were spun down and resuspended in 500 µl 
of Assay buffer. Fluorescence was measured of the FL1 
channel with flow cytometry.
Measurement of autophagy related gene 5
The Atg5 protein is a gene product which is necessary for 
the formation of autophagosomes and is thus required to 
activate autophagy and enhances susceptibility towards 
apoptotic cell death [32].
Samples were washed and pelleted at 1000 × g, resus-
pended in 1  ml PBS containing 4  % formaldehyde and 
incubated at 37 °C for 10 min. Samples were left on ice for 
1  min before centrifugation. Supernatant was discarded 
and samples were resuspended in 4  ml 100  % ice-cold 
methanol while slowing vortexing. Subsequently samples 
were incubated on ice for 30 min, after which 2 ml incu-
bation buffer was added and samples were centrifuged 
and resuspended in 100 µl incubation buffer for 10 min 
at room temperature. Samples were stained with primary 
antibody cocktail (0.05 % triton X-100, 1 % BSA and 1 µg/
ml anti Atg5 in PBS purchased from BIOCOM biotech 
Pty (Ltd) (Clubview, South Africa) and incubated at room 
temperature for 60 min. Samples were rinsed with incu-
bation buffer, centrifuged at 1000×g, resuspended in 
incubation buffer and secondary antibody cocktail was 
added for 30  min at room temperature protected from 
light. Samples were washed with incubation buffer, resus-
pended in 0.5 ml incubation buffer and were analyzed by 
flow cytometry.
Measurement of light chain 3‑II protein
The autophagy protein light chain 3 (LC3) is known to 
associate with the membranes of autophagomes and is 
essential for their formation. LC3-I is a cytosolic protein 
while the LC3-II protein is membrane bound, detection 
of the conversion of LC3-I to LC3-II is a sensitive marker 
for identifying autophagy in cells [9, 33].
Samples were washed with cold PBS and centrifuged at 
1000×g to obtain a pellet. Samples were fixed with 3 ml 
0.01  % formaldehyde in PBS for 10  min at 4  °C, centri-
fuged and was resuspended in 200  µl PBS after which 
the samples were incubated in 1 ml methanol (4  °C) for 
15  min at 4  °C. The pellet was washed twice with cold 
PBS and samples were stained with 0.5 ml antibody cock-
tail [0.05 % triton X-100, 1 % BSA and 0.5 μg/ml conju-
gated rabbit polyclonal anti-LC3B antibody purchased 
from BIOCOM biotech Pty (Ltd) (Clubview, South 
Africa)] prepared in PBS for 2  h at 4  °C. Samples were 
washed thrice with PBS containing 0.05  % triton X-100 
and 1 % BSA and were analyzed via flow cytometry.
Statistics
Quantitative and qualitative data were obtained. Quali-
tative data include SEM images and were confirmed by 
quantitative data. Quantitative data included flow cytom-
etry measurement of annexin V-FITC, caspase 3, Atg5, 
and LC3. Samples consisted of platelets collected from 
3 healthy individuals. Sample size was validated and 
confirmed by a biostatistician at the Research Office, 
Faculty of Health Sciences, University of Pretoria. Data 
were expressed as a ratio of the value measured for the 
ESE-16-treated samples compared to the vehicle-treated 
exposed samples defined as mean relative fluorescence. 
This involved flow cytometry analysis of at least 10,000–
30,000 events that was repeated in triplicate (three inde-
pendent experiments) whereafter a representative figure 
was chosen for each experiment with the use of Cyflogic 
version 1.2.1 software which calculates the means of X 
and Y co-ordinates for each treatment [17]. Statistical 
analysis consisted of ANOVA student’s t test of which a 
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P value of <0.05 was considered to be statistically signifi-
cant to compare the assessment results for the treatment 
groups and biological variations. Standard deviations 
were also determined and indicated in bar graphs. Sta-
tistically insignificant data obtained are of utmost impor-
tance to prove the hypothesis that ESE-16 does not cause 
damage to platelets per se.
Results
Scanning electron microscopy
With the use of the SEM, the surface structure and 
morphology of biological structures can be viewed to 
determine potential morphological changes [34]. SEM 
provides high-quality, high-resolution images of plate-
lets exposed to ESE-16 and appropriate controls. These 
images are shown in Fig. 1 and indicate that platelets are 
not significantly activated after exposure to ESE-16. Acti-
vation of platelets is clearly shown in the positive control 
images (Fig. 1d, e), with severe spreading and formation 
of fibrin networks, indicating initiation of coagulation.
Measurement of phosphatidyl‑serine (PS) flip via annexin 
V‑fluorescein isothiocyanate
As previously discussed, PS is externalised on platelets 
during platelet activation and apoptosis. Platelet apop-
tosis occurs through a Bak/Bax-caspase-mediated path-
way independent of activation of platelets [35]. A platelet 
isolation and activation assay was performed (data not 
shown) using the human cluster of differentiation 41 
(CD41) and human cluster of differentiation 62 (CD62P) 
markers. CD41 allows for the isolation of platelets and 
CD62 for further quantification of activation follow-
ing exposure to ESE-16 and appropriate controls. These 
experiments showed that exposure of platelets to ESE-16 
does not cause activation of platelets, thus any increase 
in PS levels is attributed to apoptosis and not activation 
of platelets.
The exposure of PS during platelet activation and 
induction of apoptosis in platelets have shown to occur 
in two distinctly different pathways [36]. Quantification 
of the extent of PS externalised in platelets is shown in 
Fig. 2. Mean fluorescence intensity (MFI) values indicate 
that the occurrence of apoptosis is not increased in a sta-
tistically significant manner in ESE-16-treated samples 
when compared to the vehicle control- and positive con-
trol platelets.
Measurement of caspase 3 activity
The activation of caspase 3, an effector caspase, results 
in the execution phase of apoptosis [36]. The activity of 
caspase 3 was determined via flow cytometry after plate-
lets were exposed to ESE-16 for 24 h. Results from three 
patients are indicated as an overview bar graph in Fig. 3, 
demonstrating that ESE-16 does not increase caspase 3 
expression in platelets of patient 1–3 after exposure to 
ESE-16 when compared to the vehicle- and positive con-
trols. This is shown by a P value of 0.539 for patient 1, 
0.389 for patient 2 and 0.100 for patient 3.
Measurement of autophagy related gene 5
The amount of Atg 5 protein expressed after exposure 
of platelets to ESE-16 was established via flow cytom-
etry. This is shown in Fig.  4 for an overview bar graph 
of all three patients’ results. Results reveal that exposure 
of platelets to ESE-16 does not increase Atg 5 levels in 
platelets.
Measurement of light chain 3‑II protein
The conversion of LC3-I to LC3-II is an essential step in 
autophagy and leads to the formation of the autophago-
some. LC3-II is carried on the inner- and outer mem-
brane of the autophagosome and was quantified by means 
of an anti-LC3B antibody. Results from all 3 patients are 
illustrated in Fig. 5 as an overview bar graph showing the 
combined results. Results indicated that LC3 levels for all 
3 patients were not increased in ESE-16-treated platelets 
when compared to that of the vehicle control platelets.
Discussion
Metastatic spread is the main source of deaths related 
to cancer and therefore provides an important research 
focus in the treatment of cancer [37]. The role of platelets 
in cancer is crucial since they support growth and metas-
tasis of tumors. The presence of platelet abnormalities in 
cancer patients has been well documented and includes 
the occurrence of thromboembolisms, and an increase in 
platelet counts, as well as platelet turnover [38].
Platelet activation by tumor cells is followed by plate-
let aggregation during which the invasive phenotype 
of tumors is enhanced by increasing the expression of 
matrix metallopeptidase-9 (MMP-9) and transforming 
growth factor β (TGFβ). Expression of MMP-9 and TGFβ 
in turn, activates nuclear factor-κB (NF-κB) resulting 
in epithelial-mesenchymal transition [39]. The effect of 
the novel anticancer compound, ESE-16, on platelets is 
thus of consequence taking into consideration its poten-
tial anticancer activity and its possible impact in cancer 
research.
The anticancer ability of this unique in silico-designed 
compound has been studied in  vitro on various cancer 
cell lines in our laboratory [17, 21, 22]. These cell lines 
include the tumorigenic human epithelial cervical HeLa 
cell line, MCF-7 breast cancer cell line, esophageal car-
cinoma SNO cell line and the metastatic MDA-MB-231 
breast cancer cell line [14–17, 21, 22]. Our studies con-
firmed that ESE-16 has similar mechanisms to that of its 
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source compound, 2-methoxyestradiol (2ME) including 
tubulin disruption, inhibition of carbonic anhydrase IX 
(CAIX) and induction of apoptosis and autophagy [14–
17, 21, 22]. In addition, it was found that the compound 
was more potent than 2ME in terms of antiproliferative 
activity at nanomolar values, while 2ME required a con-
centration between 1 and 2 μM to have any antiprolifera-
tive effects [17].
Promising results obtained from the in vitro studies in 
our laboratory subsequently advanced to ex vivo studies 
Fig. 1 SEM images of platelets of patient 3 exposed to ESE-16 and various controls. a Control platelet sample indicating normal morphology of 
platelets. b DMSO-exposed samples. c ESE-16-treated platelets indicating that the morphology of platelets was not affected following exposure to 
ESE-16. d 2MEBM-treated platelets. e Platelets treated with 4 % DMSO as a positive control for platelet damage
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where the possible anti-angiogenic properties of these 
compounds were determined. Apoptotic- and autophagic 
effects have been shown to occur in  vitro after expo-
sure to ESE-16. This along with the fact that ESE-16 was 
designed to bind to CAII, delaying early metabolism, and 
is therefore carried in the circulation, signifies the impor-
tance of studying the possible occurrence of these cell 
death mechanisms in platelets. The effect it potentiates 
Fig. 2 Overview bar graph of the percentage mean fluorescence 
intensity of apoptosis of all three patients. Exposure of platelets to 
ESE-16 did not cause apoptosis amongst all three patients when 
compared to the vehicle control- and positive control platelets (P 
value of 0.894)
Fig. 3 Overview histogram and bar graph of caspase 3 levels in 
platelets of all three patients. The vehicle control is indicated by 
the green histogram, ESE-16-treated platelets are indicated by the 
blue histogram, 2MEBM-treated samples are indicated by the yellow 
histograms and 4 % DMSO as positive control are indicated by the 
purple histogram. This overview bar graph indicates that overall the 
expression of caspase 3 is not increased significantly when compared 
to relevant controls (P value of 0.709)
Fig. 4 Overview histogram and bar graph of Atg 5 expression in 
platelets of all three patients. The vehicle control is indicated by the 
green histogram, ESE-16-treated platelets are indicated by the blue 
histogram, 2MEBM-treated samples are indicated by the yellow histo-
grams and 4 % DMSO as positive control are indicated by the purple 
histogram. Atg 5 levels are not increased in ESE-16-treated platelets of 
all three patients (P value of 0.349)
Fig. 5 Overview histogram and bar graph indicating the average 
MFI of LC3 levels in platelets of all 3 patients after exposure to ESE-16 
and various controls. The vehicle control is indicated by the green his-
togram, ESE-16-treated platelets are indicated by the blue histogram, 
2MEBM-treated samples are indicated by the yellow histograms and 
4 % DMSO as positive control are indicated by the purple histogram. 
Results show that there was a statistically insignificant difference 
between the vehicle control platelets and ESE-16-treated platelets 
between all 3 patients (P value of 0.134)
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on blood components and especially on platelets is of sig-
nificance in the study of cancer progression.
Statistically insignificant data obtained are of utmost 
importance in this project to prove the hypothesis that 
ESE-16 does not cause damage to healthy platelets per se. 
Results provide a point of reference for future investiga-
tions and since the compound does not cause morpho-
logical damage ex vivo and it does not induce apoptosis 
or autophagy in healthy platelets.
This research acquired substantial qualitative and 
quantitative data in determining the aforementioned 
effects. Qualitative data consisted of morphological stud-
ies pertaining to the influence of ESE-16 on the possible 
activation of platelets by SEM of 3 healthy females after 
exposure to ESE-16. Results showed no morphological 
changes in the platelets after exposure when compared to 
the vehicle control and positive control platelets. The lat-
ter control indicated severe activation with spreading of 
fibrin strands.
Ex vivo results are in accordance with findings by 
Stander et  al. who suggested that ESE-16 has potential 
anti-CAIX activity [22]. Carbonic anhydrase (CA) is a 
zinc (II)-dependent enzyme which catalyses the hydra-
tion of carbon dioxide into hydrogen carbonate and a 
proton; thus playing an integral role in cellular fluid bal-
ance and anion-exchange systems responsible for pH and 
CO2 homeostasis [40]. CAIX contributes to the acidic 
extracellular environment associated with tumors which, 
in turn, promotes the expression of proteinases that con-
tribute to invasion and metastasis as its expression is up-
regulated under hypoxic conditions commonly found in 
tumors [40, 41].
ESE-16 also reversibly binds to CAII in red blood cells 
as previously mentioned in order to bypass the first pass 
metabolism in the liver which is then released into the 
bloodstream from CAII resulting in increased bioavail-
ability [17]. CAII is characterized by a high affinity for 
sulphonamides, which could elucidate why ESE-16, a sul-
phamoylated analogue, does not affect platelets signifi-
cantly [41]. The effect of ESE-16 on erythrocytes along 
with its haemolytic activity after exposure to ESE-16 has 
been determined and showed no significant influence, 
even though the compound specifically binds within 
erythrocytes to CAII [42, 43].
The possible occurrence of apoptosis in ESE-16-treated 
platelets was investigated via the annexin V-FITC apop-
tosis assay which quantifies the amount of externalised 
PS. The latter characteristic is known to occur in plate-
lets following activation and apoptosis. Therefore, acti-
vation was first determined to ensure platelets were not 
activated following exposure to ESE-16 and thus not by 
externalised PS. Subsequently apoptosis was quanti-
fied and since activation did not occur, the extent of PS 
externalised was attributed to apoptosis of platelets and 
not activation. The MFI showed no statistically signifi-
cant increase in ESE-16-exposed platelets in all 3 patients 
when compared to the applicable controls.
Data were corroborated with the quantification of cas-
pase 3 levels in treated platelets. Caspase 3 is expressed 
in the executioner phase of apoptosis after formation of 
the apoptosome and activation of the initiator caspases. 
Levels of caspase 3 expression were not statistically sig-
nificantly increased in any one of the patients when com-
pared to the vehicle control.
Autophagy is not well documented in platelets and 
the presence of Atg proteins is not clearly defined in the 
process of autophagy in platelets. This is the first study 
to reveal that Atg 5 is expressed in platelets and that 
autophagy may occur in platelets. It is hypothesized that 
autophagy in platelets is of great significance as it main-
tains homeostasis within platelets and a fault herewith 
may result in deficient adhesion and aggregation of plate-
lets [10]. Results indicate that Atg 5 is not increased in 
platelets in all three patients after treatment with ESE-16 
when compared to the relevant controls.
The conversion of LC3-I to LC3-II takes place by 
means of Atg16L by conjugation to phosphatidylethan-
olamine that associates with the autophagosome mem-
brane aiding in its formation [44]. The presence of this 
conversion to LC3-II has not been documented in plate-
lets and with this study we demonstrated that LC3-II is 
present in platelets. However, LC3-II levels were not sta-
tistically significantly increased in platelets after expo-
sure to ESE-16.
This ex vivo study is the first to investigate the unique 
in silico-designed compound, ESE-16’s apoptotic- and 
autophagic effects on platelets of healthy individuals. The 
compound does not cause morphological damage ex vivo 
and it does not induce apoptosis or autophagy in plate-
lets of healthy individuals. In addition, ESE-16 decreased 
the expression of angiogenic markers including vascu-
lar endothelial growth factor warranting further ex vivo 
studies on angiogenic-, apoptotic- and autophagic- tar-
gets of cancer patients’ platelets.
Conclusion
Platelets play a crucial role in tumour development. 
In this study the ex  vivo influence of a newly, in silico-
designed potential anti-cancer compound namely 
2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-
16) was assessed on morphology of participants’ platelets 
and ESE-16’s possible apoptotic- and autophagic effect 
by means of flow cytometry through measurement of 
annexin V-FITC, caspase 3 activity, autophagy-related 
protein 5 levels and light chain 3-I to light chain 3-II 
conversion.
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This is the first ex  vivo study to highlight possible 
involvement of apoptosis and autophagy in platelets 
after exposure to this potential anti-cancer compound 
warranting further investigation concerning these cell 
death signaling pathway targets on platelets of cancer 
patients.
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